Biomay – discovery, research and development of innovative allergy therapeutics.
The privately held company pioneers the diagnostic and therapeutic use of recombinant allergens.”

Message from the CEO

Rainer HenningDear Visitor:

As you can see from our press release and the news clip below, we have received a very encouraging message from the Data Management Committee (DMC), which we have installed to perform a futility analysis of our ongoing phase IIb with our lead product BM32. The DMC has recommended that we continue the study, in which 180 patients in 6 countries have been enrolled, into the second year. This implies that there is a good chance that the study will have a positive final outcome in the fall of next year.

We are very excited about this event, as it is an important step towards clinical validation of our peptide carrier fusion vaccine platform. We are invigorated also to advance our pipeline products based on the same technology towards completion of preclinical development and clinical application. These products are indicated for house dust mite, birch, cat and ragweed allergies. We expect to have development products against all of these major allergies in the near future, and will have a product for offering for the vast majority of patients suffering from allergies against airborne agents.

At the occasion of the recent BioEurope 2013 conference, we have released an animated video, which illustrates the mechanism of action of our allergy vaccine products; please watch it here:

If you have questions and comments about us and our products, don't hesitate to contact us!

Best regards

Rainer Henning
Chief Executive Officer

Latest News

Biomay AG successfully completes interim analysis of phase IIb study with the innovative 3rd generation grass pollen allergy vaccine BM32 (16 Dec. 2013)

Biomay announced today that an interim analysis for futility has been successfully completed for an...


go to news archive